EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Use of Baseline Score in Cost-Effectiveness Modeling of Competing Interventions

Tasnim Hamza, Konstantina Chalkou, Fabio Pellegrini, Johannes Lorscheider, Jens Kuhle, Niklaus Meier, Mark Pletscher, Matthias Egger, Georgia Salanti, Next Generation Health Technology Assessment (HTx) Work Package 2 group

Value in Health · 2026-08 · 29 (8) · 1434-1442

DOI: 10.1016/j.jval.2026.03.2245 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Value in Health, 2026-08. Verfasst von Tasnim Hamza und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Cost-Effectiveness Analysis, Cost-Benefit Analysis, Glatiramer Acetate, Multiple Sclerosis, Relapsing-Remitting. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Horizon 2020 Framework Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Effectiveness AnalysisCost-Benefit AnalysisGlatiramer AcetateMultiple Sclerosis, Relapsing-RemittingImmunosuppressive AgentsHumansDimethyl FumarateRandomized Controlled Trials as TopicTreatment Effect HeterogeneityModels, EconomicRisk AssessmentQuality-Adjusted Life Years

Stichwörter der Autor:innen

baseline risk scoreheterogeneous treatment effectsnetwork meta-regression

Substanzen

Dimethyl FumarateGlatiramer AcetateImmunosuppressive Agents

Autor:innen und Institutionen

  • Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
  • Biogen Digital Health, Biogen Spain, Madrid, Spain.
  • Department of Neurology, Reha Rheinfelden, Rheinfelden, Switzerland; Department of Neurology, Research Center for Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel,…
  • Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Neurology, Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switz…
  • Institute of Pharmaceutical Medicine (ECPM), University of Basel, Basel, Switzerland; Institute of Health Economics and Health Policy, Bern University of Applied Sciences, Bern, Switzerland.
  • Institute of Health Economics and Health Policy, Bern University of Applied Sciences, Bern, Switzerland.

Förderung

  • National Institutes of Health
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
  • Horizon 2020 Framework Programme
  • Horizon 2020

Zitieren

APA

Hamza, T., Chalkou, K., Pellegrini, F., Lorscheider, J., Kuhle, J., Meier, N., Pletscher, M., Egger, M., Salanti, G., & Next Generation Health Technology Assessment (HTx) Work Package 2 group (2026). The Use of Baseline Score in Cost-Effectiveness Modeling of Competing Interventions. Value in Health, 29(8), 1434-1442. https://doi.org/10.1016/j.jval.2026.03.2245

Vancouver

Hamza T, Chalkou K, Pellegrini F, Lorscheider J, Kuhle J, Meier N, et al. The Use of Baseline Score in Cost-Effectiveness Modeling of Competing Interventions. Value in Health. 2026;29(8):1434-1442. doi:10.1016/j.jval.2026.03.2245

BibTeX
@article{Hamza2026,
  author = {Hamza, Tasnim and Chalkou, Konstantina and Pellegrini, Fabio and Lorscheider, Johannes and Kuhle, Jens and Meier, Niklaus and Pletscher, Mark and Egger, Matthias and Salanti, Georgia and Next Generation Health Technology Assessment (HTx) Work Package 2 group, Next Generation Health Technology Assessment (HTx) Work Package 2 group},
  title = {The Use of Baseline Score in Cost-Effectiveness Modeling of Competing Interventions},
  journal = {Value in Health},
  year = {2026},
  volume = {29},
  number = {8},
  pages = {1434--1442},
  doi = {10.1016/j.jval.2026.03.2245}
}
Kostenlos starten →